ZNF99 (F8281) Regulating Cell Cycle, Proliferation, Differentiation and Apoptosis in Eukaryotic Cells

Target Name: ZNF99

NCBI ID: G7652

ZNF99

ZNF99 (F8281) Regulating Cell Cycle, Proliferation, Differentiation and Apoptosis in Eukaryotic Cells

ZNF99 (F8281) is a protein that is expressed in almost all eukaryotic cells and plays an important role in a variety of cancers. It plays an important role in cell proliferation, differentiation and apoptosis and is a target of many cancers.

Function and structure of ZNF99 (F8281)

ZNF99 (F8281) is a transcription factor that belongs to the Zinc Finger Nucleotide (ZNF) family. Members of the ZNF family play an important role in a variety of cancers, including breast cancer, lung cancer, colon cancer, and neuroblastoma.

The function of ZNF99 (F8281) is mainly reflected in the regulation of cell cycle, proliferation, differentiation and apoptosis. Its expression level is higher in cells in G1 and G2 phases, while its expression level is lower in cells in S and G0 phases. This suggests that ZNF99 (F8281) plays a key role in controlling the S and G0 phases of the cell cycle.

ZNF99 (F8281) also plays an important role in cell differentiation and apoptosis. Studies have shown that ZNF99 (F8281) is highly expressed in neurons and plays an important role in neuronal apoptosis. In addition, ZNF99 (F8281) is also highly expressed in hepatocytes and splenocytes, suggesting that it may play an important biological role in the liver and spleen.

Structure and function of ZNF99 (F8281)

ZNF99 (F8281) is a zinc finger module (ZMP)-containing protein. Zinc fingers are key elements in protein-nucleic acid interactions that bind to DNA and regulate gene expression.

The ZMP domain of ZNF99 (F8281) is a 250 amino acid residue long module. This module consists of two major domains: the N-terminal domain and the C-terminal domain. The N-terminal domain contains a zinc finger, a coenzyme Q molecule (CQP), and a transient double-stranded domain. The C-terminal domain contains a zinc finger, a coenzyme Q molecule (CQP), and a short single-chain domain.

The function of ZNF99 (F8281) is mainly determined by its structure. The N-terminal domain of ZNF99 (F8281) has zinc finger and CQP binding capabilities, making it play an important role in cell cycle and molecular biology. In addition, the C-terminal domain of ZNF99 (F8281) has zinc finger and CQP binding capabilities, allowing it to play an important role in cell differentiation and apoptosis.

Pharmacological significance of ZNF99 (F8281)

ZNF99 (F8281) is a very promising drug target. Studies have shown that activation of ZNF99 (F8281) can lead to apoptosis in a variety of cancer cells, including breast cancer, lung cancer, colon cancer, and neuroblastoma.

Activation of ZNF99 (F8281) can be achieved in several ways. For example, it can be activated by anti-tumor drug small molecule compounds in certain anti-tumor drugs, which can bind to the N-terminal domain of ZNF99 (F8281), leading to its activation. In addition, the activation of ZNF99 (F8281) can also be achieved through certain signaling pathways, such as the PI3K/Akt signaling pathway.

Expression levels of ZNF99 (F8281)

ZNF99 (F8281) is highly expressed in various cancers and is an important molecule in these cancers. For example, the expression levels of ZNF99 (F8281) in breast, lung, and colon cancers are significantly higher than those in corresponding control cells. In addition, ZNF99 (F8281) is also expressed at a higher level in neurons, which

Protein Name: Zinc Finger Protein 99

Functions: May be involved in transcriptional regulation

The "ZNF99 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF99 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets